Lecanemab

The Advent of Disease-Modifying Dementia Treatments (DMDTs) Recent years have seen significant strides in our understanding of dementia, particularly Alzheimer’s disease. These advancements have led to the development of Disease-Modifying Dementia Treatments (DMDTs). These treatments aim to alter the course of disease progression and reduce its severe impact. Currently, the UK has not licensed any DMDTs, but several are undergoing various stages of development and approval. The National Institute for Health and Care Excellence (NICE) will be evaluating new Alzheimer’s […]

The Institute for Clinical and Economic Review has released a report on lecanemab, an anti-amyloid monoclonal antibody approved by the FDA for the treatment of Alzheimer’s disease. The report found that while lecanemab showed a statistically significant 27% slowing of cognitive decline compared to placebo, there are concerns about the potential harm from amyloid-related imaging abnormalities. The report also found that lecanemab’s annual price of $26,500 exceeds commonly used cost-effectiveness thresholds, and recommended efforts to achieve affordability and access. The […]